Pharmafile Logo

VJOncology

Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds.

Genetic Digital Shortlisted for PM Society Digital Award for Epilepsy Meds App

Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds, a mobile-first app that helps healthcare professionals make safer, patient-specific prescribing decisions in epilepsy care. The...

Genetic Digital

- PMLiVE

How brands can talk about sexual health on social media

Find top tips on how to navigate censorship when posting information on intimate or sexual health on social media platforms.

Say Communications

- PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

- PMLiVE

AstraZeneca shares late-stage results for Tagrisso combination in lung cancer

An estimated 2.4 million people globally are diagnosed with lung cancer each year

EU flag

EC approves SpringWorks Therapeutics’ Ezmekly to treat rare genetic disorder NF1

Neurofibromatosis type 1 affects an estimated 135,000 people in the EU

- PMLiVE

Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

- PMLiVE

NICE recommends BeOne’s Brukinsa to treat mantle cell lymphoma on NHS

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

- PMLiVE

Alnylam’s Amvuttra approved by MHRA to treat rare heart disease ATTR-CM

The drug has been authorised to treat both wild-type and hereditary forms of the disease

- PMLiVE

Impetus Digital: now offering carbon-neutral live meeting support

Impetus Digital was promoted to the Aclymate Silver Tier for their efforts in crafting carbon-neutral virtual and live meetings for life science companies.

Impetus Digital

- PMLiVE

Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

- PMLiVE

MHRA approves KalVista Pharmaceuticals’ Ekterly to treat hereditary angioedema attacks

Ekterly is now the first and only oral on-demand treatment for HAE to be approved by the UK regulator

- PMLiVE

GCI Health announces realignment of European leadership team

The new structure will see Annalise Coady step into the role of president, Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links